Compare Adaptive Biotechnologies Corp (ADPT) vs YieldMax AMD Option Income Strategy ETF (AMDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs YieldMax AMD Option Income Strategy ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.31 (market cap $4.02B), while YieldMax AMD Option Income Strategy ETF trades at $45.43. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | AMDY | |
|---|---|---|
Market Cap | $4.02B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $25.45 | $59.52 |
52-Week Low | $12.30 | $29.80 |
Enterprise Value | $4.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
AMDY trades at $45.66, up 2.47% with a bearish technical signal from moving averages. The ETF generates high weekly distributions but faces concerns about NAV erosion during AMD volatility. Recent Seeking Alpha analysis rates it HOLD, noting the strategy works best when AMD rises gradually rather than accelerating sharply.
Outlook remains cautious due to structural NAV erosion risks. The high-yield strategy provides income opportunity but requires careful timing. Key risks include AMD's performance volatility and the ETF's call spread strategy limitations during market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →
